TB-500 myths often turn a small finding into a much bigger promise. The evidence does not establish that TB-500 repairs human injuries, that adding BPC-157 doubles its effect, or that any injection site works equally well. Some of the studies behind those claims tested a different molecule altogether.
That matters when you're weighing a prescription. An interesting result can explain why researchers kept looking without telling you what a treatment will do for your injury.
TB-500 myths: how the claims are graded
Supported means the source directly backs the claim; partly means only part holds up. Not supported means the cited evidence doesn't justify it. Unknown means the needed comparison hasn't been done.
As of September 30, 2026, the day this article was written, FDA's staff review dated May 15, 2026 had identified no human studies administering the TB-500 fragment by any route. That is a gap in evidence, not proof that every possible effect is absent.
1. TB-500 is just another name for thymosin beta-4
Not supported: Thymosin beta-4, or Tβ4, has 43 amino acids, the building blocks of a peptide. A 2012 analysis in Drug Testing and Analysis identified a seven-unit fragment in a product called TB-500. Its sequence is Ac-LKKTETQ: the “Ac” marks a small chemical cap added to the front. A short piece and the whole molecule are different substances; who discovered TB-500 explains how the names became tangled.
2. Human trials have already proved TB-500 works
Not supported: A 2010 Annals of the New York Academy of Sciences trial tested full-length Tβ4 gel in 73 people with leg wounds from poor vein circulation. As of September 30, 2026, the day this article was written, the human record also included a 2025 Cardiovascular Research trial of recombinant Tβ4, produced by cells with added genetic instructions, in 96 heart-attack patients. The overall comparison found no clear difference in heart-damage size; a smaller group treated early showed a reduction. Neither trial tested the seven-unit TB-500 fragment.
3. The eye-drop results prove TB-500 injections work
Not supported: A 2015 dry-eye trial in Clinical Ophthalmology assigned 72 people to full-length Tβ4 eye drops or placebo for 28 days. Placebo is a comparison treatment without the active peptide. The two main outcomes showed no clear difference between groups, although some other measures improved. Results from drops on the eye cannot establish benefits from a different molecule given by injection.
4. TB-500 can heal any injury
Not supported: Skin, tendons and nerves are different targets, so a result in one doesn't settle the others. A 2003 study in Wound Repair and Regeneration found skin-repair effects in mice using full-length Tβ4 and a related short piece. That short piece lacked TB-500's chemical cap. The TB-500 benefits evidence needs those distinctions: which molecule, which tissue, which species and which outcome were actually tested?
5. It's natural, so it has no side effects
Not supported: The body makes full-length Tβ4; that doesn't establish the safety of a manufactured fragment or preparation. FDA's TB-500 safety entry flags possible immune reactions, where the body's defenses respond to the medicine itself. Peptide clumps and impurities may contribute. Without human exposure studies, a reliable side-effect rate is unknown; “no reported problem” and “no possible harm” are different claims.
6. Adding BPC-157 doubles the effect
Not supported: As of September 30, 2026, the day this article was written, a July 23, 2026 study in Joint Diseases and Related Surgery had tested the pair in 32 rats after Achilles-tendon repair. The combination showed no added benefit over either peptide alone; tendons were collected on day 30, with four per group used for each type of analysis. The paper calls its material TB-500 but doesn't report its sequence, leaving its exact identity unresolved. Wolverine combines BPC-157 and TB-500, but this animal result neither demonstrates a human advantage nor settles every possible use of the pair.
7. Any injection site works throughout the body
Unknown: A 2024 study in Journal of Chromatography B tracked TB-500's breakdown in laboratory samples and rats. Finding a peptide or its breakdown products away from where it was given doesn't mean it repairs a distant injury. FDA's staff review found no human studies measuring drug levels or responses by any route. There is no established human comparison showing that different injection sites deliver equal injury-healing effects.
8. The July FDA panel approved TB-500 as a medicine
Not supported: As of September 30, 2026, the day this article was written, FDA's July 23–24 meeting record concerned eligibility for the 503A Bulks List, a federal ingredient list for preparing individual prescriptions. The page, marked current as of August 6, says the committee's recommendations are nonbinding. Advice about that list is different from approval of a finished medicine. The TB-500 FDA review timeline covers the separate steps.
9. A prescription makes TB-500 okay for tested sport
Not supported: WADA, the World Anti-Doping Agency, names TB-500 under S2.3 on its 2026 Prohibited List, prohibited at all times. BPC-157 appears separately under S0, the section for unapproved substances outside the other listed groups. As of September 30, 2026, the day this article was written, WADA's September 21 release and 2027 List kept TB-500's entry, effective January 1, 2027. A prescription alone does not clear an athlete under those rules.
10. Every TB-500 label means the same ingredient
Not supported: A 2023 analysis in Drug Testing and Analysis found that products sold as TB500 or TB1000 did not consistently match earlier descriptions. The name on a label is therefore not enough to identify the substance. That finding doesn't describe every supplier, but it makes the actual ingredient and its source matter. A prescription and pharmacy record provide someone accountable for what was ordered and dispensed; they do not turn uncertain benefits into established ones.
What these grades mean for a provider visit
A useful conversation starts with the injury's diagnosis, your medicines and what treatments have already been tried. The provider can explain which evidence applies to your situation and what remains uncertain. That includes the exact ingredient, the pharmacy preparing it and how suspected side effects would be reviewed. Established treatments remain part of that conversation, even when a peptide prescription is considered.
TB-500 is coming soon to Promise; when prescribed, it will be dispensed as a compounded medication, which is different from an FDA-approved product: the formulation Promise will offer is not FDA-approved. FDA explains that compounded medicines do not undergo its premarket review. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
